Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × MAC-ST-001 × Clear all
NCT06922539 2025-12-15

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SciTech Development, Inc.

Phase 1 Recruiting
44 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡